Xavier Paliard joined Personalis in July 2017 as Vice President Immunology, Research & Development where he leads the strategy as well as R&D in the area of personalized cancer vaccines and other personalized therapeutic opportunities.
He has over 25 years of experience in Research & Development of vaccines, biologics and small molecules across an array of therapeutic areas including immuno-oncology and infectious diseases. Prior to joining Personalis, Dr. Paliard was Executive Director of Nonclinical Research at Ultragenyx. Before this, he held positions of increasing responsibility in pharmaceutical and biotechnology companies including MedImmune/AstraZeneca, Anaphore, ARYxTherapeutics, Merck and Chiron/Novartis. Dr. Paliard is a named-inventor on multiple patents; he has published in top peer-reviewed journals including Nature and Science and participated in the successful filing of multiple INDs and drug approvals. He is an Adjunct Professor at the University of New Mexico. Dr. Paliard holds a Ph.D. in Immunology and a Pharm.D. from the Claude Bernard University in Lyon, France and received his postdoctoral training from the HHMI laboratory of Dr. Philippa Marrack in Denver CO.